信置及華置:倘9月底前達500萬港人打針 額外多送凱匯一伙進行第二輪抽獎
信和集團旗下黃廷方慈善基金與華人置業集團決定,若於9月30日或之前全港有500萬名香港居民完成接種最少一劑疫苗,贊助單位將送出觀塘凱匯另一間一房住宅單位進行第二輪抽獎,該單位樓面面積約468平方呎,價值約1,200萬元。抽獎活動至今已獲逾183萬名香港居民登記。
凡於9月30日或之前,已年滿18歲並在香港完成接種至少一劑新冠疫苗的香港永久居民,均符合抽獎資格。較早前已登記參加第一輪抽獎而沒有贏得終極大獎的人士,將自動獲納入參加第二輪抽獎而毋須額外登記。
黃廷方慈善基金董事黃永光表示,社區疫苗接種是控制疫情,並讓社會回復常態的主要及有效方法,所以目前最重要是香港社會團結一致,齊心抗疫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.